GLP-1 receptor agonists and the risk of atrial fibrillation: a real-world evidence

被引：0
|
作者：
Shin, J. I. [1 ]
Xu, Y. [1 ]
Boyle, T. [2 ]
Lyu, B. [1 ]
Ballew, S. [1 ]
Selvin, E. [1 ]
Chang, A. [3 ]
Inker, L. [4 ]
Grams, M. [5 ]
机构：
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Epidemiol, Baltimore, MD USA
[2] Univ Penn, Internal Med, Philadelphia, PA USA
[3] Geisinger Commonwealth Sch Med, Internal Med, Scranton, PA USA
[4] Tufts Med Ctr, Internal Med, Boston, MA USA
[5] New York Univ, Grossman Sch Med, Internal Med, New York, NY USA
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2023年 / 197卷
关键词：
D O I：
10.1016/j.diabres.2023.110309
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
IDF2022-04
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [21] The Future of the GLP-1 Receptor Agonists
    Hirsch, Irl B.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (15): : 1457 - 1458
  • [22] Positioning on GLP-1 receptor agonists
    Gimenez, Sergio
    Piskorz, Daniel
    Martinez Demaria, Diego
    Nanfara, Silvia
    Lorenzatti, Alberto
    Zapata, Gerardo
    Aguinaga Arrascue, Luis
    Perna, Eduardo
    REVISTA DE LA FEDERACION ARGENTINA DE CARDIOLOGIA, 2021, 50 : 4 - 10
  • [23] Risk of thyroid cancer with the use of GLP-1 receptor agonists
    Gouverneur, Amandine
    Penichon, Marine
    Garrel, Renaud
    Hillaire-Buys, Dominique
    Pariente, Antoine
    Faillie, Jean-Luc
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 330 - 330
  • [24] GLP-1 Receptor Agonists: Effects on Cardiovascular Risk Reduction
    Lorber, Daniel
    CARDIOVASCULAR THERAPEUTICS, 2013, 31 (04) : 238 - 249
  • [25] Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study
    Edwards, Khary
    Li, Xilong
    Lingvay, Ildiko
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (04): : 920 - 930
  • [26] What Are the Early Selection Predictors of GLP-1 Receptor Agonists in Real-World Data for Japanese Individuals with Type 2 Diabetes?
    Suganuma, Yuka
    Ishiguro, Mizuki
    Ohno, Takayuki
    Nishimura, Rimei
    DIABETES, 2024, 73
  • [27] Impact of GLP-1 and GLP-1 Receptor Agonists on Cardiovascular Risk Factors in Type 2 Diabetes
    Verge, Danilo
    Lopez, Ximena
    CURRENT DIABETES REVIEWS, 2010, 6 (04) : 191 - 200
  • [28] GLP-1 Receptor Agonists, the Holy Grail Preventing Atrial Fibrillation in Patients With T2D?
    Stoll, Lisa
    Lo, James C.
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2023, 8 (08): : 937 - 938
  • [29] Real-world evidence on the use of benzodiazepine receptor agonists and the risk of venous thromboembolism
    Chen, Tien-Yu
    Winkelman, John W.
    Mao, Wei-Chung
    Tzeng, Nian-Sheng
    Kuo, Terry B. J.
    Yang, Cheryl C. H.
    Tsai, Hui-Ju
    Wu, Chi-Shin
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (11) : 2878 - 2888
  • [30] Real-world weight change, adherence and discontinuation among type 2 diabetes patients initiating GLP-1 receptor agonists (GLP-1RAs) in the UK
    Weiss, T.
    Iglay, K.
    Carr, R.
    Mishra, A. P.
    Yang, L.
    Rajpathak, S.
    DIABETOLOGIA, 2019, 62 : S371 - S371
12345